Inve India ▾

Epigral share price & results

Epigral Limited· Chemicals· Commodities

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Gujarat-based chlor-alkali and derivative chemicals maker, running one fully integrated complex at Dahej.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue705 ₹ crore+16.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin25.0 %−2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit100 ₹ crore−37.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity13.14 %−6.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin2.02 %−7.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)4.75 %−33.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 4 judged targets kept · 17 open · verdicts reflect calls analysed to Q1 FY27.

Epigral Limited management guidance track record on Inve: 21 targets tracked across analysed earnings calls (2 achieved, 2 missed, 17 open).

TargetOriginal wordingSaidLatest callVerdict
New Chemistry Project AnnouncementAnnounce in a couple of quarters
Call transcript, Q1 FY26 · 4 Aug 2025		Q1 FY26Q1 FY27:Announced INR 600 cr capex for Epoxy Resin & Formulations and a Multipurpose Plant, fulfilling the promise after a delay.
Call transcript, Q1 FY27 · 27 Jul 2026		Achieved
Derivatives & Specialty Revenue Contribution70% revenue contribution from Derivatives & Specialty business
Call transcript, Q4 FY25 · 8 May 2025		Q4 FY25Q1 FY27:No specific update on the contribution percentage was provided this quarter.
Call transcript, Q1 FY27 · 27 Jul 2026		On Track
CPVC Optimum Utilization~75% by FY28
Call transcript, Q4 FY26 · 2 May 2026		Q4 FY26Q1 FY27:Current CPVC utilization is low at 50-55% due to demand weakness, putting the FY28 target of 75% at risk.
Call transcript, Q1 FY27 · 27 Jul 2026		At Risk

Source: Inve Guidance Tracker for Epigral Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Epigral Limited's 21 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 18 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹896.9 +1.29% · +₹11.4

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −47.4% 1Y

₹0.8k₹1.0k₹1.2k₹1.4k₹1.6kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 3 Feb 2026Q4 FY26 — 30 Apr 2026Q1 FY27 — 27 Jul 2026

1Y: ₹1,705.8 on 24 Oct 2025 → ₹896.9. High ₹1,706.5 (29 Oct 2025), low ₹810.45 (30 Mar 2026).

Previous close
₹885.5
Market cap
₹3.8k Cr
52-week range
₹810.45 – ₹1,706.5
One year
−47.15%
Price to earnings (TTM to Jun 2026)
14.10×
Return on equity (TTM to Jun 2026)
13.14%

Overview

Symbol
NSE:EPIGRAL
Sector
Chemicals
Industry
Commodities
Exchange
NSE
Currency
INR

What Epigral Limited does

Based on the company's own presentations, annual report and earnings calls.

Epigral operates a single, fully backward- and forward-integrated manufacturing complex at Dahej, Gujarat, producing chlor-alkali products (caustic soda, caustic potash) and downstream derivative and specialty chemicals (CPVC resin, epichlorohydrin, chloromethanes, hydrogen peroxide, and a chlorotoluene value chain). It earns by selling these chemicals to a diversified customer base spanning industries such as textiles, alumina, pharmaceuticals, agrochemicals, refrigerants, pipes and fittings, and paper and pulp, both domestically and through exports. Captive chlorine, hydrogen and caustic soda generated in the chlor-alkali process feed its own derivative plants, and the company also runs a captive thermal and wind-solar power plant to supply part of its own energy needs. It has been progressively shifting its product mix from base chlor-alkali towards higher-value derivatives and specialty chemicals.

Segments

  • Chlor-Alkali
  • Derivatives & Specialty Chemicals
Manufacturing facilities
1 fully integrated complex (Dahej, Gujarat)
Chlor-Alkali capacity
421 KTPA (Caustic Soda 400 KTPA + Caustic Potash 21 KTPA)
Derivatives & Specialty capacity
250 KTPA (CPVC Resin 75, Epichlorohydrin 50, Chloromethanes 50, Hydrogen Peroxide 60, Chlorotoluenes Value Chain 15 KTPA)
Captive power capacity
132 MW thermal captive power plant + 18.34 MW wind-solar hybrid plant
Domestic market position
4th largest Caustic Soda, 5th largest Hydrogen Peroxide, 6th largest Chloromethanes producer in India
Employees
1,100+
Founded 2007Headquarters Ahmedabad, Gujarat, India Company website

How the price took the results

close before → close after

Q1 FY27
−0.5%
27 Jul
Q4 FY26
+9.3%
2 May
Q3 FY26
+12.1%
3 Feb
Q2 FY26
−7.3%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Epigral Limited

Free account: one company. Everything above stays public.

Write why you follow Epigral Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Chemicals companies

All Chemicals companies → · Chemicals earnings growth →

Learn to analyse Epigral Limited

Guides on how to read this kind of business and the numbers that matter.